CSIMarket
 


Promis Neurosciences inc   (PMN)
Other Ticker:  
 

Promis Neurosciences Inc 's Leverage Ratio

PMN's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 10.92%, Leverage Ratio fell to 1.65, below the Promis Neurosciences Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 302 other companies have achieved lower Leverage Ratio than Promis Neurosciences Inc in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 0 to 2016 .

Explain Leverage Ratio?
Who are PMN Customers?
What are PMN´s Total Liabilities?


PMN Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change 825.63 % - - - -
Y / Y Total Liabilities Change 139.07 % 188.19 % - - -
Leverage Ratio MRQ 1.65 - - - 6.37
PMN's Total Ranking # 2016 # 0 # 0 # 0 # 3422
Seq. Equity Change - - - - -89.12 %
Seq. Total Liabilities Change 10.92 % -5.48 % 28.23 % 77.83 % 33.71 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 303
Healthcare Sector # 618
Overall Market # 2016


Leverage Ratio Statistics
High Average Low
6.37 2.85 0.52
(Sep 30 2022)   (Jun 30 2022)




Financial Statements
Promis Neurosciences Inc 's Equity $ 7 Millions Visit PMN's Balance sheet
Promis Neurosciences Inc 's Total Liabilities $ 11 Millions Visit PMN's Balance sheet
Source of PMN's Sales Visit PMN's Sales by Geography


Cumulative Promis Neurosciences Inc 's Leverage Ratio

PMN's Leverage Ratio for the trailling 12 Months

PMN Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth 825.63 % - - - -
Y / Y Total Liabilities TTM Growth 139.07 % 188.19 % - - -
Leverage Ratio TTM - - - 2.69 1.09
Total Ranking TTM # 2231 # 0 # 0 # 70 # 0
Seq. Equity TTM Growth - - - - -89.12 %
Seq. Total Liabilities TTM Growth 10.92 % -5.48 % 28.23 % 77.83 % 33.71 %


On the trailing twelve months basis Despite of the net new borrowings of 10.92% during the twelve months period ending in III Quarter 2023 Promis Neurosciences Inc has managed to improve Leverage Ratio in the III Quarter 2023 to -4.3, below Promis Neurosciences Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 302, during the past 12 months, other companies have achieved lower Leverage Ratio than Promis Neurosciences Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 0 to 2231.

Explain Leverage Ratio?
Who are PMN Customers?
What are PMN´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 303
Healthcare Sector # 618
Within the Market # 2231


trailing twelve months Leverage Ratio Statistics
High Average Low
6.37 2.85 0.52
(Sep 30 2022)   (Jun 30 2022)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Intercept Pharmaceuticals inc   4.47 $ 321.317  Millions$ 71.845  Millions
Blueprint Medicines Corporation  4.46 $ 902.688  Millions$ 202.611  Millions
Kala Bio inc   4.45 $ 49.897  Millions$ 11.223  Millions
Puma Biotechnology Inc   4.26 $ 164.863  Millions$ 38.742  Millions
Celularity Inc   4.20 $ 126.945  Millions$ 30.247  Millions
Mustang Bio inc   4.13 $ 16.558  Millions$ 4.009  Millions
Mersana Therapeutics Inc   4.04 $ 210.709  Millions$ 52.195  Millions
Vbi Vaccines Inc  3.88 $ 77.194  Millions$ 19.886  Millions
Biolinerx Ltd   3.83 $ 50.702  Millions$ 13.223  Millions
Aytu Biopharma Inc   3.13 $ 100.721  Millions$ 32.167  Millions
Sarepta Therapeutics Inc   3.04 $ 2,322.856  Millions$ 764.357  Millions
Eli Lilly And Company  2.94 $ 33,266.700  Millions$ 11,307.400  Millions
Harrow Inc   2.79 $ 210.308  Millions$ 75.402  Millions
Kineta Inc   2.77 $ 7.991  Millions$ 2.889  Millions
Marinus Pharmaceuticals Inc   2.65 $ 144.368  Millions$ 54.537  Millions
Journey Medical Corporation  2.62 $ 45.447  Millions$ 17.374  Millions
Durect Corp  2.55 $ 36.752  Millions$ 14.406  Millions
Apellis Pharmaceuticals Inc   2.52 $ 585.945  Millions$ 232.271  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Gossamer Bio Inc   2.33 $ 243.308  Millions$ 104.617  Millions
Phibro Animal Health Corporation  2.27 $ 620.465  Millions$ 273.069  Millions
Uniqure N v   2.21 $ 594.878  Millions$ 268.784  Millions
Biovie Inc   2.15 $ 16.212  Millions$ 7.548  Millions
Bristol myers Squibb Company  2.14 $ 62,265.000  Millions$ 29,062.000  Millions
G1 Therapeutics Inc   2.09 $ 90.075  Millions$ 43.022  Millions
Milestone Pharmaceuticals inc   2.06 $ 58.612  Millions$ 28.504  Millions
Cerevel Therapeutics Holdings Inc   2.01 $ 549.000  Millions$ 272.962  Millions
Abeona Therapeutics Inc   2.00 $ 44.049  Millions$ 22.038  Millions
Travere Therapeutics Inc   1.98 $ 553.084  Millions$ 279.766  Millions
Maravai Lifesciences Holdings Inc   1.96 $ 1,748.259  Millions$ 892.281  Millions

Date modified: 2023-11-17T15:48:05+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com